BRIACELL THERAP (BCTX) vs NextCure, Inc. (NXTC)
- BRIACELL THERAP BCTX 3.42 −9.28%
- NextCure, Inc. NXTC 6.24 −9.30%
BRIACELL THERAP and NextCure, Inc. are both Biotechnology companies. BRIACELL THERAP and NextCure, Inc. are of similar size ($32.8M and $31.5M). NextCure, Inc. has negative trailing earnings, so its P/E is not meaningful; BRIACELL THERAP trades at 1.5×. Across the 9 metrics below, BRIACELL THERAP leads on 5 and NextCure, Inc. on 4.
Valuation
Profitability
| Metric | BCTX | NXTC | Biotechnology median |
|---|---|---|---|
| Gross margin | 0.00% | 0.00% | 65.16% |
| Operating margin | 0.00% | 0.00% | 0.00% |
| Net margin | 0.00% | 0.00% | 0.00% |
| Free cash flow margin | 0.00% | 0.00% | 0.00% |
| Return on equity | (173.55%) | (195.22%) | (56.36%) |
| Return on assets | (139.20%) | (121.60%) | (48.04%) |
| Return on invested capital | (3,311.00%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack